Attend this conference on substance use disorders to hear the latest research and find guidance that enhances your care for patients.
Substance use disorders remain among the most complex and consequential conditions encountered in healthcare, affecting patients, families, and communities across every setting of care. Clinicians are challenged not only by evolving evidence and guidelines but also by high rates of comorbidity, social determinants of health, and rapidly changing treatment landscapes. This conference is designed to help practitioners stay current, confident, and clinically effective.
The program provides a comprehensive, evidence-based update across the full spectrum of substance use disorders, spanning neuroscience, developmental and lifespan perspectives, pharmacologic and behavioral treatments, and recovery-oriented systems of care. Sessions are intentionally structured to translate current research into practical, actionable strategies that can be applied across diverse clinical settings.
The conference emphasizes an interactive and collegial learning environment, with dedicated time for discussion, audience questions, and case-based exploration of complex clinical scenarios. Attendees have the opportunity to engage directly in dialogue around challenging cases, evolving best practices, and real-world implementation—fostering meaningful exchange across disciplines and practice settings.
Whether you practice in primary care, psychiatry, psychology, social work, nursing, emergency medicine, or integrated care settings, this conference offers a practice-relevant update to strengthen your approach to screening, diagnosis, and treatment of substance use disorders and common co-occurring conditions.
MDs/Doctoral-Level Professionals
Super Early Bird Registration (before August 31, 2026): $975.00
Early Bird Registration (before November 30, 2026) $1,035.00
Regular Registration (after December 1, 2026): $1,139.00
Other Professionals or Trainees
Super Early Bird Registration (before August 31, 2026): $875.00
Early Bird Registration (before November 30, 2026): $931.00
Regular Registration (after December 1, 2026): $1,035.00
Price: $75.00
The conference syllabus is a printed book with all slide presentations and space to take notes adjacent to each slide. Please note that all syllabus purchases are non-refundable and non-shippable and must be picked up onsite at the conference.
As an alternative to purchasing a conference syllabus, we provide all attendees with completely free access to all slide presentations in digital PDF format prior to the conference. This is an environmentally friendly alternative and helps keep costs lower for all attendees. The e-syllabus will be available for 30 days after the conference.
A refund minus a $100.00 administrative fee will be issued for refund requests received by January 2, 2027. Payments made may not be applied to future conferences or other educational activities. There are no exceptions to these policies.
Board certification and recertification exams are critical career moments. That is why you should rely on the Massachusetts General Hospital Psychiatry Update & Board Preparation, Fourth Edition. It puts our 80+ years of clinical experience at your fingertips to help you prepare for your exam.
Purchase a print copy of our Board Preparation book here!
This program is intended for:
Our conference lets you engage dozens of renowned clinician-researchers, get your clinical questions answered, and translate enhanced knowledge into optimal patient care.
Here are some of the ways that participants plan to change their clinical practice as a result of attending our conference:
Check Back Soon for Accreditation Information.
Policy on Faculty and Provider Disclosure:
Disclosure Information
In accordance with the disclosure policy of MGH Institute of Health Professions as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all financial relationships with ineligible companies for the past 24 months, as defined below:
Ineligible Companies
The ACCME defines an “Ineligible company” as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” For more information, visit accme.org/standards.
Financial Relationships
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.
Mitigation of Financial Relationships
All financial relationships are reviewed to determine which ones are relevant, and then measures are taken to mitigate all relevant financial relationships and ensure that they do not insert commercial bias into the content of the education.
Laura G. Kehoe, MD, MPH, FASAM
Medical Director, Substance Use Disorder Bridge Clinic
Massachusetts General Hospital
Assistant Professor of Medicine, Harvard Medical School
John F. Kelly, PhD, ABPP
Elizabeth R. Spallin, Professor of Psychiatry, Harvard Medical School
Director, MGH Recovery Research Institute
Program Director, MGH Addiction Recovery Management Service (ARMS)
Associate Director, MGH Center for Addiction Medicine
David H. Rubin, MD
Director, Division of Professional and Public Education, MGH
Executive Director, MGH Psychiatry Academy and MGH Visiting, MGH
Assistant Professor, Harvard Medical School
Timothy E. Wilens, MD
Chief, Division of Child and Adolescent Psychiatry,
(Co) Director, Center for Addiction Medicine,
Massachusetts General Hospital
Professor of Psychiatry,
Harvard Medical School
President-Elect, American Academy of Child and Adolescent Psychiatry
Please check back later for the speakers.
We have a dedicated staff member who is available by phone 5 days per week between 8 am and 5 pm by calling 866-644-7792 or email at mghcme@mgh.harvard.edu. All inquiries will be dealt with in a timely (within one business day) and professional manner. Requests for credits or refunds will be reviewed by the Director of the Division of Professional and Public Education, Massachusetts General Hospital. Please refer to our cancellation policy for additional information.”